Quicksilver Scientific

Free Shipping on Orders over $300 (Excludes , , )
Quicksilver Scientific Logo
Main Menu
Main Menu
0
0
Subtotal: 0.00

No products in the cart.

Full Spectrum Hemp Extract References

  1. Hudak, J. The farm bill, hemp legalization and the status of CBD: an explainer. Available at: https://www.brookings.edu/blog/fixgov/2018/12/14/the-farm-bill-hemp-and-cbd-explainer/. Dec 2018. Accessed April 29, 2019.
  2. Yang L, Li FF et al. Cannabinoid receptor CB2 is involved in tetrahydrocannabinol-induced anti-inflammation against lipopolysaccharide in MG-63 cells. Mediators Inflamm. 2015; 2015: 362126.
  3. Day J. Botany meets archaeology: people and plants in the past. Journal of Experimental Botany. 2013; 64(18): 5805–5816.4.
  4. Naranjo P, Schultes R et al. (Eds) Urgent need for the study of medicinal plants. Ethnobotany: Evolution of a Discipline, Dioscorides Press, Portland, OR (1995), pp. 362-368.5.
  5. Mechoulam, R. (ed.) in Cannabinoids as Therapeutic Agents 1–19 (CRC, Boca Raton, 1986).
  6. Elsohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci. 2005; 78(5): 539– 548.
  7. Mechoulam R, Peters M et al. Cannabidiol—recent advances. Chem Biodivers. 2007; 4(8): 1678–1692.
  8. Premoli M, Aria F et al. Cannabidiol, recent advances and new insights for neuropsychiatric disorders treatment. Life Sciences. 2019; 224: 120–127.
  9. Maccarrone M, Bab I, et al. Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci. 2015 May; 36(5): 277–296.
  10. Russo EB. Beyond Cannabis: Plants and the Endocannabinoid System. Trends Pharmacol Sci. 2016; 37(7): 594-605
  11. Matsuda LA, Lolait SJ et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990; 346: 561-564
  12. Munro S, Thomas KL et al. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993; 365: 61-65
  13. Járai Z, Wagner J. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA. 1999 Nov 23; 96(24): 14136–14141
  14. Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol (Suppl 1). 2006; 147: S163–S171.
  15. Ryberg E, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007; 152: 1092–1101.
  16. Glass M, Dragunow M et al. Cannabinoid receptors in the human brain: A detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience. 1997; 77(2): 299–318.
  17. Brown SM, Wager-Miller J et al. Cloning and molecular characterization of the rat CB2 cannabinoid receptor. Biochimica et Biophysica Acta. 2002; 1576(3): 255–264
  18. Grotenhermen F. Cannabinoids. Curr Drug Targets CNS Neurol Disord. 2005; 4(5): 507–530.
  19. Devane WA, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992; 258(5090): 1946–1949
  20. Vaughan CW, Christine MJ. Retrograde signaling by endocannabinoids. Handb Exp Pharmacol. 2005; (168): 367-83
  21. Kano M, Ohno-Shosaku T. Retrograde signaling at central synapses via endogenous cannabinoids. Mol Psychiatry. 2002; 7(3): 234-235.
  22. Morales P, Hurst DP et al. Molecular targets of the phytocannabinoids: A complex picture. Prog Chem Org Nat Prod. 2017; 103: 103–131.
  23. Pretsch CM, Freyberg J et al. Effects of cannabidiol on brain excitation and inhibition systems; a randomized placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder. Neuropsychopharmacology. 2019. 44: 1398-1405.  
  24. Fasinu PS, Phillips S et al. Current status and prospects for cannabidiol preparations as new therapeutic agents. Pharmacotherapy. 2016; 36: 781–796
  25. Morales P, Reggio PH et al. An overview on medicinal chemistry of synthetic and natural derivatives of cannabidiol. Front Pharmacol. 2017; (8) p 422
  26. Russo EB, Burnett A et al. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 2005; 30: 1037–1043
  27. Esposito G, Scuderi C et al. Cannabidiol reduces Ab-induced neuroinflammation and promotes hippocampal neurogenesis through PPARg involvement. PLoS One. 2011; 6: e28668
  28. Bakas T, Devenish S et al. The actions of cannabidiol and 2-arachidonyl glycerol on GABA-A receptors. Proceedings of the 26th Annual Symposium on the Cannabinoids, International Cannabinoid Research Society, Bukovina, 2016; pp. 28.
  29. Pacher P, Kunos G. Modulating the endocannabinoid system in human health and disease–successes and failures. FEBS J. 2013; 280(9): 1918-43
  30. McPartland JM, Guy GW et al. Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system. PLoS One. 2014; 9(3): e89566
  31. Di Marzo V, Maccarrone M. FAAH and anandamide: is 2-AG really the odd one out? Trends Pharmacol Sci. 2008; 29: 229–233.
  32. Melamede, R. 2015, February 24. Dr Robert Melamede PhD on the Endocannabinoid System.  Available at: https://www.youtube.com/watch?v=pvaF1r0HL6Y&app=desktop.  Accessed April 28, 2019.
  33. Juknat A, Pietr M, Kozela E. et al. Differential transcriptional profiles mediated by exposure to the cannabinoids cannabidiol and Δ9-tetrahydrocannabinol in BV-2 microglial cells. Br J Pharmacol. 2012; 165(8): 2512-28.
  34. Blasco-Benito S, Seijo-Vila M et al. Appraising the “entourage effect”: Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer. Biochem Pharmacol. 2018; 157: 285-293
  35. Russo EB, Guy GW (2006). A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses. 66: 234–246.
  36. Witkamp R, Meijerink J. The endocannabinoid system: an emerging key player in inflammation. Curr Opin Clin Nutr Metab Care. 2014; 17(2): 130-8.
  37. Lau BK, Cota D, Cristino L, et al. Endocannabinoid modulation of homeostatic and non-homeostatic feeding circuits. Neuropharmacology. 2017; 124: 38-51.
  38. Malfait AM, Gallily R et al. The non-psychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA. 2000; 97(17): 9561–6.
  39. Hampson AJ, Grimaldi M et al. Neuroprotective antioxidants from marijuana. Ann N Y Acad Sci. 2000; 899: 274-82.
  40. Pucci M, Rapino C et al. Epigenetic control of skin differentiation genes by phytocannabinoids. Br J Pharmacol. 2013; 170(3): 581-91
  41. Schmidt E (2010). Production of essential oils. In: Baser KHC, Buchbauer G (eds). Handbook of Essential Oils: Science, Technology, and Applications. CRC Press: Boca Raton, FL, pp. 83–120.
  42. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011; 163(7): 1344–1364.
  43. Study by Quicksilver Scientific. 10 Person intra-absorption comparison of liposomal and non-liposomal cannabidiol.
  44. El-Alfy AT, Ivey K. Antidepressant-like effect of 19 -tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacol Biochem Behav. 2010; 95: 434–442.
  45. Ashton CH, Moore PB et al. Endocannabinoid system dysfunction in mood and related disorders. Acta Psychiatr Scand. 2011; 124(4): 250-61.
  46. Babson KA, Sottile J et al. Cannabis, cannabinoids, and sleep: A review of the literature. Curr Psychiatry Rep. 2017; 19(4): 23.
  47. Kleiner D, Ditrói K Orv Hetil. The potential use of cannabidiol in the therapy of metabolic syndrome. Orv Hetil. 2012;153(13): 499-504.
  48. Fernandez-Ruiz J, Sagredo O et al. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br J Clin Pharmacol. 2013; 75(2): 323–333.
  49. Velayudhan L, Van Diepen E et al. Therapeutic potential of cannabinoids in neurodegenerative disorders: a selective review. Curr Pharmaceut Des. 2014; 20(13): 2218–2230.
  50. Baul HS, Manikandan C et al. Cannabinoid receptor as a potential therapeutic target for Parkinson’s Disease. Brain Research Bulletin. 2019; 146: 244–252.
  51. Himadri Shekhaar Baul, Ceera Manikandan, Dwaipayan Sen Devinsky O, Marsh E et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2015; 15(3): 270–278.
  52. Baker D, Pryce G et al. The endocannabinoid system and multiple sclerosis. Curr Pharmaceut Des. 2008; 14(23): 2326–2336.
  53. Massi P, Solinas M et al. Cannabidiol as potential anticancer drug. Br J Clin Pharmacol. 2013; 75(2): 303–312.
  54. Korem N, Zer-Aviv TM et al. Targeting the endocannabinoid system to treat anxiety-related disorders. J Basic Clin Physiol Pharmacol. 2016;27(3): 193-202.
  55. Blessing EM, Steenkamp MM et al. Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics. 2015; 12(4): 825–836.
  56. Neya LJ, Matthews A et al. Cannabinoid interventions for PTSD: Where to next? Prog Neuropsychopharmacol Biol Psychiatry. 2019; 93: 124–140.
  57. Russo EB. Cannabinoids in the management of difficult to treat pain. Therapeut Clin Risk Manag. 2008; 4: 245–259.
  58. S. Peat, Using cannabinoids in pain and palliative care. Int J Palliat Nurs. 2010; 16; pp. 481–485.
  59. Gajofatto A.  Refractory trigeminal neuralgia responsive to nabiximols in a patient with multiple sclerosis. Mult Scler Relat Disord. 2016; 8: 64–65.
  60. Sabatino M, Fabiana P et al. Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. Br J Pharmacol. 2011 Feb; 162(3): 584–596.
  61. Burstein S.  Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorgan Med Chem. 2015; 23: 1377–1385.
  62. Maresz EJ, Carrier ED et al. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem. 2005; 95; pp. 437–445.
  63. Kachan V, David P. Cannabinoids and autoimmune diseases: A systematic review. Autoimmunity Rev. 2016; 15: 513–528
  64. Ribeiro A, Almeida V et al. Cannabidiol improves lung function and inflammation in mice submitted to LPS-induced acute lung injury. Immunopharmacol Immunotoxicol. 2015; 37, pp. 35–41.
  65. McAllister SD, Murase R. Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res. 2011; 129(1): 37–47.
  66. Russo EB. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett. 2008; 29(2): 192-200.
  67. Grinspoon, L. A novel approach to the symptomatic treatment of autism. O’Shaughnessy’s, 2010; Summer Issue.
  68. Karhson DS, Krasinska KM et al. Plasma anandamide concentrations are lower in children with autism spectrum disorder. Mol Autism. 2018; 12(9): 18.
  69. Borrelli F, Fasolino I. et al. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem Pharmacol. 2013; 85: 1306–1316.
  70. Di Carlo G, Izzo AA et al. Cannabinoids for gastrointestinal diseases: potential therapeutic applications. Expert Opin Invest Drugs. 2003; 12: 39–49
  71. Merritt JC, Crawford PC et al. Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology. 1980; 87(3): 222–228.
  72. El-Remessy AB, Al-Shabrawey M. Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am J Pathol. 2006; 168:  235–244.
  73. Durst R, Lotan C et al. The potential for clinical use of cannabinoids in treatment of cardiovascular diseases. Cardiovascular Therapeutics. 2011; 29: 17–22.
  74. Rajesh M, Mukhopadhyay P et al. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol. 2010; 56(25): 2115–2125.

 

0
    0
    Your Cart
    You're 50.00 away from free shipping.
    Your cart is empty
    Continue Shopping
      Calculate Shipping
      Apply Coupon